BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors

BRAVESST2: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

IDENTIFIER (ClinicalTrials.gov): NCT07129252

DRUG/TREATMENT: CRN09682

PHASE: 1/2

STATUS: Recruiting

SPONSOR: Crinetics Pharmaceuticals, Inc.

Download the BRAVESST2 Study Brochure here >>>

DESCRIPTION:

BRAVESST-2 is a Phase 1/2, first-in-human clinical trial studying a new investigational medication called CRN09682. This treatment is designed for people with metastatic or locally advanced neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), or other solid tumors that express somatostatin receptor type-2 (SST2).

What is CRN09682?

CRN09682 is a potential new antibody-drug conjugate (ADC) that is given by intravenous (IV) infusion. It is designed to:

• Recognize and attach to SST2-positive cancer cells, and

• Deliver a cancer-fighting drug (MMAE) directly to those cells

The goal is to slow or stop tumor growth while limiting exposure to healthy cells.

Why This Study Matters

This study aims to understand:

• Safety — what side effects occur and at what doses

• Tolerability — how participants handle the medication

• How the drug behaves in the body

• Early signs of effectiveness in SST2-expressing tumors

  
  

Because this is a first-in-human study, CRN09682 has not yet been approved by any regulatory authority.

Who Can Join

You may be eligible if you:

• Are 18 years or older

• Have progressive, metastatic, or locally advanced NET, NEC, or another SST2-positive solid tumor

  • Examples include: pancreatic, lung, or GI NETs; small or large cell lung cancer; extra-pulmonary NEC; colorectal, gastric, breast, hepatocellular, nasopharyngeal carcinomas; Merkel cell carcinoma; and melanoma Crinetics_BRAVESST2_Bi-fold Par…

• Have not had surgery in the last 90 days

• Have not received prior treatment with MMAE-based therapies

Your study team will confirm your full eligibility.

What Participation Involves

• Screening period: up to 28 days

• IV treatment every 21 days (Cycle 1, then additional cycles)

• Safety follow-up: 30 days after the last dose

• Long-term follow-up: every 3 months

• Optional tumor biopsies

What to Expect

• The study drug, lab tests, imaging, and all study procedures are provided at no cost

• Travel expenses may be reimbursed

• You may stop participation at any time

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to  view this trial here.

CONTACT

Name: Crinetics Clinical Trials

Phone Number: 833-276-4636

Email: clinicaltrials@crinetics.com

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.